NASDAQ:STRO Sutro Biopharma Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Sutro Biopharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $10.31 +0.01 (+0.10 %) (As of 09/28/2020 12:00 AM ET) Add Compare Share Today's Range$10.09Now: $10.31▼$10.8050-Day Range$8.40MA: $10.23▼$13.1552-Week Range$6.00Now: $10.31▼$13.91Volume227,264 shsAverage Volume177,215 shsMarket Capitalization$369.91 millionP/E RatioN/ADividend YieldN/ABeta0.6 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingSutro Biopharma has received a consensus rating of Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.83, Sutro Biopharma has a forecasted upside of 82.7% from its current price of $10.31.Amount of Analyst CoverageSutro Biopharma has only been the subject of 2 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesSutro Biopharma has received 85 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSutro Biopharma has received 92 “underperform” votes. (Add your “underperform” vote.)Community SentimentSutro Biopharma has received 51.98% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Sutro Biopharma and other stocks. Vote “Outperform” if you believe STRO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe STRO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSutro Biopharma does not currently pay a dividend.Dividend GrowthSutro Biopharma does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sutro Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,176,672.00 in company stock.Percentage Held by InsidersOnly 14.50% of the stock of Sutro Biopharma is held by insiders.Percentage Held by Institutions67.96% of the stock of Sutro Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Sutro Biopharma are expected to decrease in the coming year, from ($2.05) to ($2.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sutro Biopharma is -9.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sutro Biopharma is -9.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSutro Biopharma has a P/B Ratio of 2.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.37 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:STRO Previous Symbol CUSIPN/A CIKN/A Webwww.sutrobio.com Phone650-392-8412Debt Debt-to-Equity Ratio0.12 Current Ratio7.29 Quick Ratio7.29Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$42.74 million Price / Sales8.65 Cash FlowN/A Price / Cash FlowN/A Book Value$4.24 per share Price / Book2.43Profitability EPS (Most Recent Fiscal Year)($2.43) Net Income$-55,740,000.00 Net Margins-43.34% Return on Equity-53.40% Return on Assets-34.91%Miscellaneous Employees141 Outstanding Shares35,879,000Market Cap$369.91 million Next Earnings Date11/13/2020 (Estimated) OptionableNot Optionable $10.31 +0.01 (+0.10 %) (As of 09/28/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive STRO News and Ratings via Email Sign-up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter. Sutro Biopharma (NASDAQ:STRO) Frequently Asked Questions How has Sutro Biopharma's stock been impacted by Coronavirus (COVID-19)? Sutro Biopharma's stock was trading at $8.11 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, STRO shares have increased by 27.1% and is now trading at $10.31. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Sutro Biopharma? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Sutro Biopharma. When is Sutro Biopharma's next earnings date? Sutro Biopharma is scheduled to release its next quarterly earnings announcement on Friday, November 13th 2020. View our earnings forecast for Sutro Biopharma. How were Sutro Biopharma's earnings last quarter? Sutro Biopharma Inc (NASDAQ:STRO) issued its earnings results on Thursday, August, 6th. The company reported ($0.60) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.59) by $0.01. The company had revenue of $9.47 million for the quarter, compared to analysts' expectations of $8.80 million. Sutro Biopharma had a negative return on equity of 53.40% and a negative net margin of 43.34%. View Sutro Biopharma's earnings history. What price target have analysts set for STRO? 8 Wall Street analysts have issued 1-year target prices for Sutro Biopharma's shares. Their forecasts range from $17.00 to $21.00. On average, they anticipate Sutro Biopharma's share price to reach $18.83 in the next twelve months. This suggests a possible upside of 82.7% from the stock's current price. View analysts' price targets for Sutro Biopharma. Are investors shorting Sutro Biopharma? Sutro Biopharma saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 1,340,000 shares, an increase of 78.1% from the August 31st total of 752,300 shares. Based on an average daily volume of 343,500 shares, the short-interest ratio is currently 3.9 days. View Sutro Biopharma's Short Interest. Who are some of Sutro Biopharma's key competitors? Some companies that are related to Sutro Biopharma include Cortexyme (CRTX), Sangamo Therapeutics (SGMO), Beam Therapeutics (BEAM), Coherus Biosciences (CHRS), Kymera Therapeutics (KYMR), Compugen (CGEN), I-Mab (BDTX), Regenxbio (RGNX), Adaptimmune Therapeutics (ADAP), Translate Bio (TBIO), Atara Biotherapeutics (ATRA), Alector (ALEC), Replimune Group (REPL), Adverum Biotechnologies (ADVM) and Vericel (VCEL). View all competitors. What other stocks do shareholders of Sutro Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Pfizer (PFE), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), IDEAYA Biosciences (IDYA), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), Xeris Pharmaceuticals (XERS) and AbbVie (ABBV). Who are Sutro Biopharma's key executives? Sutro Biopharma's management team includes the following people: Mr. William J. Newell, CEO & Director (Age 61)Dr. Trevor J. Hallam, Chief Scientific Officer (Age 60)Dr. Arturo M. Molina, Chief Medical Officer (Age 60)Dr. James R. Swartz Sc.D., Ph.D., Founder and Member of Scientific Advisory BoardMr. Edward C. Albini, CFO & Sec. (Age 61) When did Sutro Biopharma IPO? (STRO) raised $75 million in an initial public offering on Thursday, September 27th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. What is Sutro Biopharma's stock symbol? Sutro Biopharma trades on the NASDAQ under the ticker symbol "STRO." Who are Sutro Biopharma's major shareholders? Sutro Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include BVF Inc. IL (10.20%), Point72 Asset Management L.P. (2.58%), Logos Global Management LP (1.56%), Barclays PLC (1.02%), Granite Point Capital Management L.P. (0.65%) and Driehaus Capital Management LLC (0.28%). Company insiders that own Sutro Biopharma stock include Arturo Md Molina, Daniel H Petree, John Gordon Freund, Merck & Co, Inc, Trevor Hallam and William J Newell. View institutional ownership trends for Sutro Biopharma. Which institutional investors are selling Sutro Biopharma stock? STRO stock was sold by a variety of institutional investors in the last quarter, including Driehaus Capital Management LLC, and Jacobs Levy Equity Management Inc.. Company insiders that have sold Sutro Biopharma company stock in the last year include John Gordon Freund, and Trevor Hallam. View insider buying and selling activity for Sutro Biopharma. Which institutional investors are buying Sutro Biopharma stock? STRO stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, Point72 Asset Management L.P., Logos Global Management LP, Granite Point Capital Management L.P., Bessemer Group Inc., California Public Employees Retirement System, Trexquant Investment LP, and Goldman Sachs Group Inc.. Company insiders that have bought Sutro Biopharma stock in the last two years include Arturo Md Molina, Merck & Co, Inc, and William J Newell. View insider buying and selling activity for Sutro Biopharma. How do I buy shares of Sutro Biopharma? Shares of STRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Sutro Biopharma's stock price today? One share of STRO stock can currently be purchased for approximately $10.31. How big of a company is Sutro Biopharma? Sutro Biopharma has a market capitalization of $369.91 million and generates $42.74 million in revenue each year. The company earns $-55,740,000.00 in net income (profit) each year or ($2.43) on an earnings per share basis. Sutro Biopharma employs 141 workers across the globe. What is Sutro Biopharma's official website? The official website for Sutro Biopharma is www.sutrobio.com. How can I contact Sutro Biopharma? Sutro Biopharma's mailing address is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. The company can be reached via phone at 650-392-8412. This page was last updated on 9/28/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
